Go Ad-Free
    My Alerts
    Moneycontrol
    Moneycontrol PRO
    Loans
    Loans
    HomeNewsBiocon

    Jump to

    • NPPA's move to positively impact insulin sales: Biocon

      Speaking to CNBC-TV18, Kiran Mazumdar Shaw, chairman and ,managing director of Biocon said," I am glad that NPPA has given us this price increase. It still puts us at a discount to other multinationals and importers of insulin but at least one step at a time."

    • Clinigene & Syngene may list in a year's time: Biocon

      In an exclusive interview with CNBC-TV 18, Kiran Mazumdar Shaw, CMD of Biocon says that Clingene & Syngene to undergo transformation in the business model and would wait for a year before listing the IPO. She also expects Pfizer revenues in the next 24-36 months.

    Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347